Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…Andrograholide protect microglial activation via inhibiting mitochondrial ROS generation and NLRP3 inflammasome activation in in-vitro and in-vivo model of Parkinson’s disease
Objective: Parkinson's disease (PD) is a distressing neurodegenerative disorder effecting nearly 2-3% of the total population greater than 65 years old . Several mechanisms have…The add-on effect of Lactobacillus plantarum PS128 in patients with Parkinson’s disease: A pilot study
Objective: We aimed to investigate the add-on effect of Lactobacillus plantarum PS128 (PS128) in patients with Parkinson’s disease (PD). Background: PS128 is a specific probiotic…Claims Data Analysis of Parkinson’s Disease Medication Utilization
Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…An Analysis of Parkinson’s Disease Medication Treatment Patterns among Medicaid Patients
Objective: To describe patient demographic and medication utilization patterns within a state Medicaid program for patients diagnosed with Parkinson’s disease (PD). Background: Little is known…Opicapone management: A 2-year follow up real- life practice study
Objective: The aim of this work is to show our clinical experience with opicapone in real practice in a cohort of 68 parkinsonian patients followed…Effectiveness of onabotulinumtoxinA on reduction of rest tremor in Parkinson’s disease: A pilot study
Objective: To determine the feasibility of a prospective study design aimed specifically at comparing the effect of onabotulinumtoxinA (BOT-A) to placebo injections on persons with…Physiologically-based pharmacokinetic modeling of nilotinib to determine serum, cerebrospinal fluid, and brain exposures
Objective: To construct a physiologically-based pharmacokinetic (PBPK) model for predicting nilotinib pharmacokinetics (PK) in plasma and cerebrospinal fluid (CSF); and, to compare model-predicted serum and…Sleep-related Symptoms in Multiple System Atrophy: Determinants and Impact on disease severity
Objective: To investigate the prevalence and determinants of sleep-related symptoms in multiple system atrophy (MSA) and the impact of sleep disturbances on disease severity. Background:…Morphology and Signal Changes of the Lentiform Nucleus Based on Susceptibility Weighted Imaging in Parkinsonism predominant Multiple System Atrophy
Objective: This present case-control study was aimed to investigate both morphological and signal intensity changes in susceptibility weighted imaging(SWI) of the Lentiform Nucleus (LN) for…
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 149
- Next Page »